Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM37CX4)

Drug Name
IC14 Drug Info
Synonyms CD14 antibody
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Sepsis 1G40-1G41 Phase 2 [2]
Therapeutic Class
Antiviral Agents
Cross-matching ID
TTD Drug ID
DM37CX4

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUAMN monocyte differentiation antigen CD14 (CD14) TTCLGZ8 CD14_HUMAN Inhibitor [1]
Monocyte differentiation antigen CD14 (CD14) TT6I7DC CD14_HUMAN Not Available [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Monocyte differentiation antigen CD14 (CD14) DTT CD14 11.082 7.527 8.321 7.815
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monocyte differentiation antigen CD14 (CD14) DTT CD14 5.74E-14 1.61 1.11
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)
2 ClinicalTrials.gov (NCT00233207) IC14 Antibodies to Treat Individuals With Acute Lung Injury. U.S. National Institutes of Health.
3 IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4.